Mesoblast resubmits biologics license application (bla) with united states food & drug administration (fda) for approval of ryoncil® in children with steroid-refractory acute graft-versus-host disease (sr-agvhd)

New york, july 08, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its bla for approval of ryoncil® (remestemcel-l) in the treatment of children with sr-agvhd.
MESO Ratings Summary
MESO Quant Ranking